Neonc Technologies Holdings, Inc. income statement
In fiscal 2025, Neonc Technologies Holdings, Inc. reported revenue of $39,990, down 51.8% on the year before, operating income of −$58.2m (a -145637.5% margin) and net income of −$62.1m, or −$3.20 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Quarter | 2024 Q2Jun 2024 | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research and development | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 3 |
| Selling, general and administrative | — | — | — | 0 | — | — | — | — |
| General and administrative | 0 | 0 | 1 | — | 1 | 1 | 2 | 1 |
| Operating income | −1 | −2 | −2 | −32 | −6 | −7 | −14 | −14 |
| Interest expense | 1 | 0 | −0 | 0 | 0 | 1 | 1 | 0 |
| Net income | −5 | −2 | −2 | −32 | −6 | −9 | −16 | −14 |
| Diluted EPS | −$0.27 | −$0.12 | −$0.13 | −$1.78 | −$0.30 | −$0.45 | −$0.72 | −$0.58 |
Compare with peers
- Lyell Immunopharma, Inc. income statement
- AIM Immunotech Inc. income statement
- Ibio, Inc. income statement
- Lisata Therapeutics, Inc. income statement
- Celldex Therapeutics, Inc. income statement
Head to head: LYEL vs NTHIAIM vs NTHIIBIO vs NTHI
More: Biotechnology stocks compared, Health Care sector, rankings of US companies